EyePoint Pharmaceuticals (EYPT)
(Delayed Data from NSDQ)
$10.33 USD
+0.42 (4.24%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $10.33 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
EYPT 10.33 +0.42(4.24%)
Will EYPT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for EYPT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EYPT
Intra-Cellular (ITCI) Soars 9.6%: Is Further Upside Left in the Stock?
Compared to Estimates, EyePoint Pharmaceuticals (EYPT) Q4 Earnings: A Look at Key Metrics
EYPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will EyePoint Pharmaceuticals (EYPT) Report Negative Q4 Earnings? What You Should Know
Vericel Corporation (VCEL) Q4 Earnings Beat Estimates
Here's Why Momentum in EyePoint Pharmaceuticals (EYPT) Should Keep going
Other News for EYPT
EyePoint Pharmaceuticals Earns ‘Outperform’ Rating on Promising Duravyu Data and Strategic FDA Alignment
TD Cowen Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT)
Buy Rating Affirmed for EyePoint Pharmaceuticals Amidst Promising DURAVYU Trial Results
EyePoint Pharmaceuticals to Highlight DURAVYUTM (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024
EyePoint announces developments on DURAVYU